LABD Direxion Daily S&P Biotech Bear 3X ETF
ETF 7.70 DelayedETF quote, holdings, sector allocation, technicals, and options analytics. Expected move IV rank history Fibonacci levels
Market data may be delayed, incomplete, or inaccurate. Not a recommendation to buy, sell, or hold any security. Verify quotes with your broker before trading. See Terms §17.
- 52-Week Range
- $5.81 – $27.60
- YTD
- -63.83%
- IV Rank (30D)
- 28.64
- Straddle Price
- $2.15
- P/C Vol Ratio
- 0.71
- Open
- $7.51
- Day Range
- $7.28 – $7.83
- Volume
- 5,213,838
- Prev Close
- $7.42
Direxion Daily S&P Biotech Bear 3X ETF (LABD) ETF
No description available.
- Exchange
- ARCX
- Inception
- 2015-05-28
- Has Options
- Yes
- Expense ratio
- 1.07% prospectus, filed Mar 3, 2026
- Assets
- $79M shares × price, Nov 13, 2026
- Trailing yield
- 6.20% paid quarterly
- Average daily volume
- $191M 30 sessions
- Holdings
- 10 top 10 are 0.0%
- Listed
- May 28, 2015 NYSE Arca
- Last fee change
- -3 bp filed Feb 26, 2025
Moves with. Small caps over large (18% of its variance, beta -3.25); US large-cap stocks (10% of its variance, beta -1.27); Value over growth (8% of its variance, beta 1.42); Long Treasuries (6% of its variance, beta -1.73). These factors explain 46% of its daily moves over the last year.
Stated objective. The Fund seeks daily investment results, before fees and expenses, of 300% of the inverse (or opposite) of the daily performance of the Index. The Fund does not seek to achieve its stated investment objective for a period of time different than a trading day. (from the fund's prospectus)
All 10 holdingsFlow historyOverlap toolAll Inverse Equity ETFs
- Jul 2026
- −$28M latest reported month
- Latest 3 months
- +$16M +29.2% of assets
- Latest 12 months
- +$122M +224.6% of assets
View as a table
| Month | Net flow |
|---|---|
| Jul 2026 | −$28M |
| Jun 2026 | +$25M |
| May 2026 | +$18M |
| Apr 2026 | −$11M |
| Mar 2026 | +$27M |
| Feb 2026 | −$934K |
| Jan 2026 | +$775K |
| Dec 2025 | −$7.8M |
| Nov 2025 | +$31M |
| Oct 2025 | +$31M |
| Sep 2025 | +$26M |
| Aug 2025 | +$10M |
Net creations and redemptions from the fund's SEC filings, which become public about 60 days after each quarter. Every month since 84 months ago
| Fund | Overlap | Fee | Assets | 1Y | |
|---|---|---|---|---|---|
| SQQQProShares UltraPro Short QQQ | — | 0.94% | $1.7B | −37.7% | compare |
| SOXSDirexion Daily Semiconductor Bear 3X ETF | — | 1.00% | $1.5B | −92.7% | compare |
| SHProShares Short S&P500 | — | 0.88% | $960M | −9.2% | compare |
| PSQProShares Short QQQ | — | 0.95% | $622M | −10.5% | compare |
| SDSProShares UltraShort S&P500 | — | 0.91% | $405M | −19.3% | compare |
The largest other funds in the Inverse Equity category.
- Authorized participants
- 7 active of 7 with agreements; top 3 did 83%
- Created · redeemed
- $647M · $629M over the fiscal year
- Redemptions in kind
- 0% creations 0% in kind
- Creation unit
- 50,000 shares
- Securities lending
- authorized, none lent
- Diversification status
- Non-diversified may concentrate in fewer issuers
From the fund's annual census filing with the SEC. In-kind redemptions are what let an ETF shed appreciated securities without realising gains.
| Ex-Date | Pay Date | Amount | Type |
|---|---|---|---|
| 2026-09-22 | 2026-09-29 | $0.0707 | CD |
| 2026-06-23 | 2026-06-30 | $0.0752 | CD |
| 2026-03-24 | 2026-03-31 | $0.0854 | CD |
| 2025-12-23 | 2025-12-31 | $0.2287 | CD |
| 2025-09-23 | 2025-09-30 | $0.0260 | CD |
| 2025-06-24 | 2025-07-01 | $0.0370 | CD |
| Symbol | Name | Weight % | Asset Class | Country |
|---|---|---|---|---|
| — | GOLDMAN FINL SQ TRSRY INST 506 | 48.52% | Cash/Money Market | — |
| — | DREYFUS GOVT CASH MAN INS | 29.32% | Cash/Money Market | — |
| — | GOLDMAN SACHS FIN GOV 465 INSTITUT | 9.15% | Cash/Money Market | — |
| — | DREYFUS TRSRY SECURITIES CASH MGMT | 3.48% | Cash/Money Market | — |
| — | SPSIBI SWAP ASSET LEG | -1.73% | Derivative | — |
| — | SPSIBI SWAP ASSET LEG | -5.51% | Derivative | — |
| — | SPSIBI SWAP ASSET LEG | -17.73% | Derivative | — |
| — | SPSIBI SWAP ASSET LEG | -57.98% | Derivative | — |
| — | SPSIBI SWAP ASSET LEG | -83.37% | Derivative | — |
| — | SPSIBI SWAP ASSET LEG | -133.68% | Derivative | — |
| Category | Weight | Value | Positions |
|---|---|---|---|
| Short-term investment | 137.54% | $74.6M | 4 |
| DO | -12.51% | $-6782592 | 6 |
| Month | '21 | '22 | '23 | '24 | '25 | '26 | Avg |
|---|---|---|---|---|---|---|---|
| Jan | -24.56% | 66.12% | -23.90% | 6.82% | -4.63% | -9.82% | 1.67% |
| Feb | 18.34% | 8.27% | 24.44% | -30.17% | 8.61% | -1.94% | 4.59% |
| Mar | 20.31% | -14.67% | 24.68% | 20.50% | 14.86% | -9.85% | 9.30% |
| Apr | -4.16% | 85.35% | -14.70% | 33.60% | -24.81% | -7.08% | 11.37% |
| May | 12.23% | 12.44% | -10.08% | -6.09% | 7.99% | -15.43% | 0.18% |
| Jun | -20.54% | -34.81% | 5.51% | -6.27% | -6.15% | -43.39% | -17.61% |
| Jul | 35.71% | -23.00% | -5.37% | -18.07% | -10.36% | 17.71% | -0.56% |
| Aug | -22.96% | -22.69% | 15.81% | -9.12% | -13.27% | -28.53% | -13.46% |
| Sep | 20.00% | 14.60% | 34.55% | -1.18% | -21.78% | 8.15% | 9.06% |
| Oct | 0.99% | -13.74% | 18.14% | 2.67% | -28.18% | -6.43% | -4.42% |
| Nov | 34.57% | -9.16% | -32.35% | -3.82% | -29.66% | -1.20%* | -6.94% |
| Dec | -8.40% | -5.06% | -37.24% | 29.46% | -8.03% | -- | -5.85% |
| Total | 43.37% | 5.82% | -29.33% | -0.57% | -74.38% | -70.17% | -20.88% |
Quick-reference for reading the values below. Indicators combine to confirm a view — no single one is a trade signal on its own.
- SMA 20 / 50 / 200 — price above = uptrend, below = downtrend. SMA 50 crossing SMA 200 is the golden/death cross.
- EMA 12 / 26 — faster-reacting averages; 12 above 26 is short-term bullish.
- MACD — bullish when MACD > signal (green badge), bearish when below. Divergence from price often precedes reversals.
- ADX (14) — trend strength regardless of direction. <20 range, 20–25 weak trend, 25–50 trend, >50 strong trend.
- +DI / −DI — +DI > −DI favors bulls; the reverse favors bears. Read alongside ADX.
- RSI (14) — <30 oversold, >70 overbought. 40–60 is neutral; trending names can stay extreme.
- Stochastic %K / %D — <20 oversold, >80 overbought. %K crossing %D is an early momentum signal.
- Williams %R — inverted scale: <−80 oversold, >−20 overbought.
Oscillators work best in range-bound markets; in strong trends they give premature reversal signals.
- Bollinger Bands — price at upper band = overbought, lower = oversold. Narrow bands (squeeze) often precede expansion.
- OBV — cumulative volume; rising OBV confirms uptrend, falling OBV confirms downtrend. Divergence from price is a warning.
- Vol SMA 20 / Vol ROC — today's volume vs. 20-day average. Positive ROC with price move = conviction.
- ATR / True Range — average daily $ move; sizing and stop-loss reference.
- HV 20 / 30 / 60 — realized (historical) volatility. Compare to IV on the options cards: IV > HV = rich premium.
Confluence matters: trend + momentum + volume agreeing carries far more weight than any single indicator. For how these feed the spread scanner score, see the algorithm docs →
Trend Indicators
Momentum Oscillators
Volume & Volatility
Data Summary
LABD Stock Analysis Report
Direxion Daily S&P Biotech Bear 3X ETF
Executive Summary
Overall Assessment: BULLISH with Confidence Level 7/10
LABD is a -3x leveraged inverse ETF designed to profit from declines in the S&P Biotech Index. The fund is currently positioned advantageously for its mandate, with technical momentum turning positive and significant net inflows over the past 12 months (+$122M, +224.6% of assets). However, this is a directional derivatives product, not a traditional equity investment, and investors should understand that the fund's value decays over time due to daily rebalancing mechanics and significant cash drag from treasury holdings.
Key Drivers:
- Positive MACD histogram (0.22) and bullish crossover setup indicate nascent upward momentum
- Strong recent inflows despite negative July outflow (-$28M), suggesting persistent investor demand for bearish biotech positioning
- Price trading above all major moving averages (SMA 20: $7.64, SMA 50: $7.20) with current price $8.56
- High implied volatility (IV 102.6%, IV Rank 21.4%) provides optionality value
Primary Risks:
- Massive cash position (86.1% in treasury instruments) creates significant drag on returns
- Negative beta (-3.16) and -0.47 correlation mean this fund's performance is structurally tied to inverse market movements—if biotech rallies sharply, LABD declines rapidly
- Historical volatility extremely elevated (HV60 89.2%), indicating extreme price swings
- Daily rebalancing creates compounding decay in ranging or choppy markets
- Fund size ($137M AUM) is relatively small, limiting liquidity cushion
Investment Thesis: LABD is appropriately positioned for investors with a bearish biotech outlook or seeking portfolio hedging. Recent technical strength and positive fund flows suggest sentiment remains tilted toward biotech weakness. However, the structural mechanics of 3x leveraged inverse ETFs mean this is a tactical, time-sensitive position best suited for traders or temporary hedges, not core holdings.
Recent News Sentiment Impact: News headlines are universally neutral and generic, focusing on fund performance rankings in inverse ETF categories (May 2024, April 2024, March 2024, October 2023). No catalysts or biotech-specific developments mentioned. The neutral sentiment aligns with the fund's mechanical rebalancing rather than responding to fundamental news about underlying biotech holdings.
Technical Analysis
Trend Direction
Short-term (1-4 weeks): BULLISH
- Price at $8.56 is 2.8% above the SMA 20 ($7.64), indicating recent upward momentum
- EMA 12 ($8.02) is above EMA 26 ($7.70), with +0.32 differential—classic early-stage bullish alignment
- MACD histogram positive at 0.22 and trending toward signal line crossover completion
- Stochastic readings (K: 78.50, D: 79.66) near overbought but not yet confirming reversal
Medium-term (1-3 months): NEUTRAL-TO-BEARISH SETUP
- Price is 18.2% below the SMA 200 ($12.92)—significant bearish deviation
- The SMA 200 represents the major structural resistance and long-term downtrend anchor
- MACD histogram remains positive, but the distance from signal line suggests momentum is fragile
- ADX (14) at 15.30 indicates a ranging market, not a sustained trend—this is critical for a leveraged inverse ETF
Long-term (3-12 months): BEARISH TECHNICAL STRUCTURE
- The $12.92 SMA 200 represents a major technical ceiling
- Fund's position $4.36 below this level reflects sustained bearish biotech performance
- Mean reversion logic suggests price could face selling pressure if it approaches the 200-day MA
Support/Resistance Levels
| Level | Type | Significance | |-------|------|---| | $8.77 | Resistance | Upper Bollinger Band; 2.5% above current price | | $8.56 | Current | Recent support holding; breaking above $8.77 opens path to $9.00 psychological level | | $7.64 | Support | SMA 20; acted as interim floor; 10.8% downside | | $7.20 | Support | SMA 50; secondary support level; 15.9% downside | | $6.50 | Major Support | Lower Bollinger Band; critical support; 24.1% downside |
Critical Observation: The support/resistance framework shows the fund is in a narrow trading range between $6.50-$8.77 (29.66% Bollinger Band width). This 4.5-month range lacks breakout conviction.
Momentum Signals
RSI (14): 59.59 – NEUTRAL
- Positioned in the middle of the 30-70 neutral zone
- Neither overbought nor oversold; suggests room for move in either direction
- Not yet at levels that would trigger mean-reversion signals
- For a leveraged inverse fund, this neutral reading is healthy (not extended)
MACD Signal: BULLISH MOMENTUM BUILDING
- MACD line (0.32) > Signal line (0.10) with positive histogram (0.22)
- This represents early-stage bullish momentum, not yet confirmed
- The +0.22 histogram is growing but modest—momentum is present but fragile
- A crossover above signal line by signal line moving upward would confirm strength
- Caveat: In ranging markets (ADX 15.30), MACD can whipsaw frequently
Stochastic %K and %D: OVERBOUGHT READINGS
- %K at 78.50 and %D at 79.66 are in overbought territory (>70)
- Williams %R at -14.85 is also deep in overbought zone (<-20)
- These readings suggest recent buyers have overextended and a pullback toward the SMA 20 ($7.64) is likely
- This is a conflict signal: MACD bullish, but momentum oscillators overbought
Bollinger Bands Analysis
- Position: Price ($8.56) is in upper half of band, 90% toward upper band ($8.77)
- Band Width: 29.66% indicates moderate volatility expansion—not a squeeze, but not extreme
- Signal: Neutral positioning; bands are neither compressed (suggesting breakout potential) nor expanded (suggesting exhaustion)
- Implication: The fund could consolidate here or push toward upper band ($8.77), but a band-walk at upper levels would require sustained momentum
Volume Analysis
Critical Data Quality Flag: OBV Reading is Problematic
- On-Balance Volume at -$224.3 billion is nonsensical for a $137M fund
- This suggests either: (a) data error, (b) OBV calculation issue with leveraged products, or (c) the metric is irrelevant for synthetic/ETF structures
- Volume SMA 20 at 25.5M shares/day is meaningful and usable
Volume Rate of Change: -40.81% – BEARISH VOLUME SIGNAL
- Trading volume has declined 40.81% vs. the 20-day average
- This divergence is concerning: price is rising while volume is falling
- Classic weak-hand rally indicator; suggests the uptrend lacks institutional conviction
- For LABD specifically, lower volume could indicate reduced hedging/positioning demand
Institutional Interest Signal:
- Declining volume on price strength suggests retail or algorithmic positioning rather than institutional accumulation
- The recent +$16M inflows (3-month basis) and +$122M (12-month) came during higher-volatility periods, not current rally phase
- This implies institutions may be reducing positions into recent strength
News & Sentiment Analysis
Recent Headlines Summary
All six news articles are generic category listings from Zacks Investment Research and Seeking Alpha, published between March 2023 and May 2024:
- May 2024: "5 Inverse ETFs That Gained More Than 20% in April" (Zacks)
- April 2024: "5 Best Inverse-Leveraged ETFs of Last Week" (Zacks)
- March 2024: "Best Inverse/Leveraged ETFs of Last Week" (Zacks)
- March 2024: "LA
LABD Options Activity & IV Rank
LABD IV rank history, 52-week IV rank and IV percentile →
Volatility Metrics
Options Flow · All expiries
ATM Options Pricing
Chain Summary
LABD Adjusted Options
1 series · quotes as of Nov 13, 2026LABD's option chain includes one adjusted series. It delivers something other than 100 LABD shares, so its prices don't line up with the standard LABD options at the same strike.
Why they price differently: a standard option delivers 100 shares, so its price follows the stock. An adjusted contract delivers what a split, merger, spinoff or special dividend left in place of those 100 shares: more or fewer shares, shares of another company, or cash. The strike and the 100 multiplier stay the same, so its price follows the value of that package divided by 100, not LABD's share price. Option calculators, implied volatility and expected moves that assume 100 LABD shares get these contracts wrong. They also trade thinly with wide quotes, and new strikes or expiries are rarely added, so they fade out as they expire.
LABD1 Adjusted LABD series
- Each contract delivers
- 10 LABD shares
- What it prices off
- The package is worth about $74.20 at current prices, so these contracts price off $0.74 a unit, not LABD's $7.42. A call is in the money when that figure is above its strike, a put when it is below.
- Why it exists
- Left by LABD's 1-for-10 reverse split on Sep 29, 2025.
| Contract | Bid | Ask | Last | Volume | Open int. | Exercise value |
|---|---|---|---|---|---|---|
| Jan 15, 2027 $3 call | — | $0.75 | $0.55 | 1 | 684 | $0.00 |
| Jan 15, 2027 $6 call | — | $0.75 | $0.10 | 1 | 188 | $0.00 |
| Jan 15, 2027 $8 call | — | $0.70 | $0.05 | 2 | 786 | $0.00 |
| Jan 15, 2027 $10 call | — | $3.40 | $0.15 | 3 | 1,694 | $0.00 |
| Jan 15, 2027 $14 call | — | $3.40 | $0.05 | 2 | 962 | $0.00 |
| Jan 15, 2027 $15 call | — | $3.40 | $0.07 | 5 | 187 | $0.00 |
| Jan 15, 2027 $10 put | $7.80 | $11.40 | $9.75 | 1 | 431 | $9.26 |
| Jan 15, 2027 $12 put | $9.80 | $13.40 | $10.70 | 17 | 302 | $11.26 |
By expiry (2)
| Expiry | Calls | Puts | Strikes | Open int. | Volume |
|---|---|---|---|---|---|
| Jan 15, 2027 | 28 | 28 | 1 to 28 | 6,369 | 344 |
| Jan 21, 2028 | 10 | 10 | 1 to 10 | 35 | 1 |
Each spread is ranked by a composite score built in three stages. Full documentation →
score = P(profit) × (credit / spread_width)
P(profit) from short leg delta (1 − |delta|), penalised above 85%. Credit uses mid-price to handle illiquid chains fairly.
Calendars: the long leg is valued at the short leg’s expiration (Black-Scholes at its current IV) across the range of prices the short leg’s IV implies, giving the best-case profit (R/R = that over the debit) and P(profit).
RR and BF (30-delta) from the persisted per-symbol skew snapshot — wing strikes picked by real greeks.delta, not a moneyness proxy. Put skew boosts bull puts, penalises bear calls. High butterfly boosts iron condors. Calendars are skew-neutral.
- RSI <40 bullish / >60 bearish
- MACD crossover + histogram trend
- Price vs SMA 50 & SMA 200
- Stochastic %K <20 / >80
- Williams %R <−80 / >−20
- Blended ATR + straddle expected-move penalty
- Bollinger Band signal (+ counter-trend penalty)
- BB width — vol contraction boost for ICs
- IV rank ≥ 75 → strong boost for credit spreads
- IV rank < 25 → penalty (selling cheap vol)
- Min open interest across all legs
- OI < 100 → −0.10 · OI < 500 → −0.05
score = base_score × skew_multiplier × tech_multiplier
Both multipliers are shown per spread. Beta is informational only — ATR already captures realized vol. Full algorithm documentation →
Scanning bull put, bear call, iron condor and calendar spreads…
Estimated net dealer gamma is at the 49th percentile of this name's own daily history, within its typical range. This describes current positioning; it is not a forecast or a trading signal.
Net dealer gamma is an estimate of the aggregate gamma held by options market makers across this name's option chain, weighted by open interest. Dealer positions aren't public, so it uses a standard simplifying assumption: dealers are treated as long the calls and short the puts that are open. Actual dealer books can differ.
Gamma percentile ranks today's estimate against this name's own daily history, from 0% (the lowest reading on record) to 100% (the highest). Raw gamma scales with how much open interest a chain carries, so it isn't comparable across names; the percentile is. The badge marks the bottom 20% as low and the top 20% as high.
Tilts run from −1 to +1 and show how lopsided the estimated dealer exposure is. GEX tilt compares call gamma with put gamma. Vanna tilt describes how the hedge would shift if implied volatility changed, and charm tilt how it would shift with the passage of time.
This card describes estimated positioning and where it sits historically. It is not a forecast of price direction or volatility and not a trading signal. Market-wide view: Dealer positioning screener.
IV(put wing) − IV(ATM), in vol pointsHow much the OTM put trades above (or below) the at-the-money strike. Measures the height of the put-side tail relative to ATM — i.e. how expensive crash insurance is on this name.
- Positive (typical) — wing IV > ATM IV. Standard equity put skew: portfolios bid up crash protection, so OTM puts trade richer than ATM.
- Near zero or negative (unusual) — wing IV ≤ ATM IV. Flat or inverted put side. Common when there's no fear demand, in tightly mean-reverting names, or right after an earnings catalyst clears.
- Percentile vs own 3-yr history: high = wings rich (good time to sell wing premium); low = wings cheap (good time to buy protection).
- Not directional — high or low wings don't predict up or down moves. It's a price tag on tail insurance, not a forecast.
IV(call wing) − IV(put wing), equal delta on each sideWhich side of the smile is the market paying up for? Measures the tilt of the surface — call skew vs put skew at matched deltas.
- Negative (typical) — puts richer than calls. Standard equity behavior: hedging demand makes puts carry a premium. Most large-caps sit in the −1 to −5 vol-point range.
- Strongly negative (< −5 pts) — heavy downside hedging, elevated fear, or an upcoming catalyst (earnings, FDA, macro event). Worth flagging.
- Positive — calls richer than puts. Unusual for equities; signals bullish momentum, short-squeeze positioning, or takeover/M&A speculation.
- Near zero — symmetric surface. Market sees roughly equal up/down risk. Rare for large-caps; more common in commodities and FX.
IV(call wing) − IV(ATM), in vol pointsThe same measure on the upside: how the OTM call is priced against the at-the-money strike.
- Negative (typical) — calls trade below ATM for most stocks and indices, so the sign alone says little.
- Percentile vs own history: high = upside calls unusually rich for this name (squeezes, takeover talk, commodity supply scares); low = calls cheaper than usual.
Put or call vs ATM tells you how expensive that tail is. Risk Reversal tells you which side is favored. Combined:
- High wing percentile + deeply negative RR → strong put bid; stress or major event priced in. Owning protection costs a premium; selling put premium is dangerous.
- Low wing percentile + near-zero RR → complacency; insurance cheap and balanced. Good environment to add cheap downside hedges.
- Positive RR + elevated wings → call-side fear-of-missing-out; common in squeeze setups. Upside calls expensive, downside puts not bid.
Percentile is the rank of today's reading within ~3 years of this symbol's own history. High percentile = wings are rich relative to history; not a directional signal. Skew is read off the chain in real time, not from CBOE SKEW.
Loading the implied volatility surface…
Loading the implied volatility smile…
Risk Metrics
Analysis Details
Data Points: 251
Period: 252 trading days
Negative beta - stock moves opposite to market
LABD Institutional Ownership (13F)
Filings for 2026-09-30Institutional managers with $100M+ AUM file Form 13F-HR quarterly, due 45 days after quarter end. Holdings are reported gross at quarter-end market value — they are a snapshot, not a real-time position.
- Shares — long equity positions in this name, aggregated across share classes.
- Calls / Puts — notional value of long call / put exposure where this ticker is the underlying.
- % of Float — holder's reported shares divided by the latest diluted shares outstanding. Sums above 100% indicate large custodian / prime broker positions where the same shares are reported by multiple filers.
- Custodian badge — filers with more than 5,000 holdings are typically broker-dealers / custodians reporting customer-held shares, not active managers.
Each filer is counted once at its latest 13F-HR filing. New filings are ingested on a weekly cadence.
| # | Filer | Notional Value | % of Total | Period |
|---|---|---|---|---|
| 1 | Susquehanna International Group, LLP Custodian | $8.49M | 85.45% | 2026-06-30 |
| 2 | Citadel Advisors LLC Custodian | $990.66K | 9.98% | 2026-06-30 |
| 3 | Jane Street Group, LLC Custodian | $454.21K | 4.57% | 2026-09-30 |
| # | Filer | Notional Value | % of Total | Period |
|---|---|---|---|---|
| 1 | Citadel Advisors LLC Custodian | $2.87M | 74.68% | 2026-06-30 |
| 2 | Susquehanna International Group, LLP Custodian | $758.66K | 19.76% | 2026-06-30 |
| 3 | Jane Street Group, LLC Custodian | $213.71K | 5.57% | 2026-09-30 |
Regulatory short-interest reports publish on a bi-weekly settlement cadence; short-volume is reported daily by the trade-reporting facilities. Float is derived from insider-ownership filings.
- Short Interest — total shares currently sold short as of the settlement date. Lags real time by ~8 business days.
- SI % of Float — short interest / free float. The key crowding metric.
- Days to Cover — short interest / avg daily volume. How many full trading days it would take shorts to buy back. High DTC + catalyst = squeeze fuel.
- Short Vol Ratio — today's short-sale volume / total volume. Intraday selling pressure proxy (not the same as short interest).
- Free Float — shares available for public trading (total shares minus insider / restricted).
- Float % — free float / shares outstanding. <50% = tightly held, more prone to squeezes.
- SI % of Float < 5% — typical, no particular signal.
- 5–15% — elevated; watch for catalysts (earnings, guidance, macro).
- 15–30% — heavily shorted; tight-float names in this range have produced notable squeezes historically.
- >30% — extreme; borrow is likely expensive and squeeze risk is material.
- Days to Cover > 5 combined with high SI% amplifies squeeze potential.
- Trend matters more than level. Rapidly rising short interest often precedes negative catalysts or heavy hedging.
- A sudden drop in SI after a rally may indicate a squeeze in progress.
Short interest is reported mid-month and end-of-month; short volume is daily.
Click any bar to view the full quote for that stock.
| Symbol | Name | Weight % | Price | 1 Day | 1 Week | 1 Month |
|---|